Pneumonia is an infection of one or both lungs caused by bacteria, viruses, or fungi, leading to inflammation and fluid accumulation in alveoli with potential respiratory compromise.
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
Regeneron said the Phase 3 NIMBLE trial of cemdisiran in generalized myasthenia gravis met primary and key secondary endpoints at week 24. The company said a U.S. regulatory application has been submitted and EU filings are planned for 2026.
Breath Diagnostics said the FDA granted Breakthrough Device Designation to its OneBreath platform for pre-operative assessment of postoperative pneumonia risk in adults undergoing elective cardiac surgery. The single-breath test analyzes exhaled volatile organic compounds using LC-MS and is intended for use with clinical evaluation and standard risk assessment tools.
Research shows chloramine disinfection successfully stopped a Legionnaires' disease outbreak in Minnesota, while clinical data reveals Legionella pneumonia has 11.9% 30-day mortality and disproportionately affects immunocompromised patients. The studies highlight both prevention strategies and diagnostic challenges.
The World Health Organization published blueprints for urgently needed antibiotics targeting drug-resistant infections, while CARB-X awarded $1.2 million for novel antibiotic research and the FDA issued guidance on antibiotic duration limits in livestock.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
A measles exposure occurred on February 18 at Nemours Children's Hospital emergency department in Delaware. State health officials are conducting contact tracing and urging unvaccinated exposed individuals to receive MMR vaccine within 72 hours.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07759583 |
Effects of Buteyko Breathing Versus Incentive Spirometry on Oxygen Saturation, Dyspnoea, Exercise Tolerance, and Sputum Clearance in Patients With Smog Induced Pneumonia |
RECRUITING | NA |
| NCT07744555 |
Change in the Proportion of Correct Interpretations of Pulmonary Opacities |
ACTIVE_NOT_RECRUITING | NA |
| NCT07708610 |
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes |
NOT_YET_RECRUITING | |
| NCT07703852 |
Pilot Study to Study the Time Between Pleuropulmonary Ultrasound and Antibiotic Therapy Prescription in Patients Admitted to the Emergency Department for Suspected Pneumonia |
NOT_YET_RECRUITING | |
| NCT07681583 |
Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score |
RECRUITING | |
| NCT07634419 |
Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress |
NOT_YET_RECRUITING | NA |
| NCT07631377 |
The LalelaLung Study: Digital Stethoscope Clinical Evaluation |
NOT_YET_RECRUITING | PHASE4 |
| NCT07615010 |
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure |
RECRUITING | PHASE2 |
| NCT07612605 |
Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07604103 |
Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination |
RECRUITING | PHASE3 |
